Elizabeth Reed

Elizabeth Reed

Senior Vice President and General CouncilatTravere Therapeutics· In proxies 2021–2023

Pay in FY2022+6% from the year before · Travere Therapeutics stock -32.2% the same year

Elizabeth Reed was paid $2.0M in FY2022 (Dec), up 6%. Travere Therapeutics stock fell 32.2% that year.

Pay$100 in the stock at the end of FY20 → $77
Pay is from the Summary Compensation Table of each Travere Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Travere TherapeuticsPublic company · 5 yr
    • Senior Vice President and General Council2021 – Present · 5 yrStock in role +84%

Roles come from the proxy statements of each company.

Activity

No new filings about this person in the feed.

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?